Protagonist Therapeutics Inc


Prices are adjusted according to historical splits.

Protagonist Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$1.61 billion
Book Value:
Revenue TTM:
Operating Margin TTM:
Gross Profit TTM:
$26.58 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Protagonist Therapeutics Inc had its IPO on 2016-08-11 under the ticker symbol PTGX.

The company operates in the Healthcare sector and Biotechnology industry. Protagonist Therapeutics Inc has a staff strength of 103 employees.

Stock update

Shares of Protagonist Therapeutics Inc opened at $27.58 at the start of the last trading session i.e. 2023-06-03.

The stocks traded within a range of $27.27 - $28.26, and closed at $28.2.

This is a +2.58% increase from the previous day's closing price.

A total volume of 725,400 shares were traded at the close of the day’s session.

In the last one week, shares of Protagonist Therapeutics Inc have increased by +12.26%.

Protagonist Therapeutics Inc's Key Ratios

Protagonist Therapeutics Inc has a market cap of $1.61 billion, indicating a price to book ratio of 1.9246 and a price to sales ratio of 13.2717.

In the last 12-months Protagonist Therapeutics Inc’s revenue was $859000 with a gross profit of $26.58 million and an EBITDA of $-145250000. The EBITDA ratio measures Protagonist Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Protagonist Therapeutics Inc’s operating margin was -17029.45% while its return on assets stood at -31.09% with a return of equity of -54.13%.

In Q1, Protagonist Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

Protagonist Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-3.07 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Protagonist Therapeutics Inc’s profitability.

Protagonist Therapeutics Inc stock is trading at a EV to sales ratio of 5.843 and a EV to EBITDA ratio of -1.6038. Its price to sales ratio in the trailing 12-months stood at 13.2717.

Protagonist Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$239.86 million
Total Liabilities
$23.23 million
Operating Cash Flow
$9.83 million
Capital Expenditure
Dividend Payout Ratio

Protagonist Therapeutics Inc ended 2023 with $239.86 million in total assets and $0 in total liabilities. Its intangible assets were valued at $239.86 million while shareholder equity stood at $-570480000.00.

Protagonist Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $23.23 million in other current liabilities, 1000.00 in common stock, $-570480000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $127.69 million and cash and short-term investments were $230.76 million. The company’s total short-term debt was $2,599,000 while long-term debt stood at $0.

Protagonist Therapeutics Inc’s total current assets stands at $235.74 million while long-term investments were $0 and short-term investments were $103.07 million. Its net receivables were $51000.00 compared to accounts payable of $4.02 million and inventory worth $0.

In 2023, Protagonist Therapeutics Inc's operating cash flow was $9.83 million while its capital expenditure stood at $10000.

Comparatively, Protagonist Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Protagonist Therapeutics Inc stock is currently trading at $28.2 per share. It touched a 52-week high of $28.259 and a 52-week low of $28.259. Analysts tracking the stock have a 12-month average target price of $34.4.

Its 50-day moving average was $23.32 and 200-day moving average was $14.35 The short ratio stood at 3.96 indicating a short percent outstanding of 0%.

Around 167.4% of the company’s stock are held by insiders while 10409.5% are held by institutions.

Frequently Asked Questions About Protagonist Therapeutics Inc

The stock symbol (also called stock or share ticker) of Protagonist Therapeutics Inc is PTGX

The IPO of Protagonist Therapeutics Inc took place on 2016-08-11

Similar Industry Stocks (Biotechnology)

Last Price
Uflex Limited (500148)
Barclays PLC (BCLYF)
IVP Limited (507580)

Most Active

Last Price
Zomato Limited (ZOMATO)
Tesla Inc (TSLA)
Yes Bank Limited (YESBANK)

Top Gainers

Last Price
AEye Inc (LIDRW)

Top Losers

Last Price


Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.


7707 Gateway Boulevard, Newark, CA, United States, 94560-1160